1. Home
  2. GOVX vs ENSC Comparison

GOVX vs ENSC Comparison

Compare GOVX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.83

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.43

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOVX
ENSC
Founded
2001
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.9M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
GOVX
ENSC
Price
$0.83
$0.43
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
196.2K
21.4M
Earning Date
04-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.24
EPS
N/A
N/A
Revenue
$2,489,145.00
$5,066,650.00
Revenue This Year
N/A
$55.01
Revenue Next Year
N/A
$1,033.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.23
52 Week High
$4.40
$2.75

Technical Indicators

Market Signals
Indicator
GOVX
ENSC
Relative Strength Index (RSI) 43.96 65.10
Support Level $0.64 $0.27
Resistance Level $2.00 $0.65
Average True Range (ATR) 0.09 0.08
MACD 0.03 0.02
Stochastic Oscillator 56.54 27.08

Price Performance

Historical Comparison
GOVX
ENSC

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: